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Background: Chemotherapy-induced amenorrhea (CIA) is one of the most frequent therapy-related adverse events
observed in breast cancer patients who have undergone chemotherapy. Although the characteristics of CIA have
been studied in Western countries, little is known about CIA in Asian. We conducted a retrospective analysis to
assess the characteristics and influencing factors of CIA and its association with menopause in Chinese women who
underwent adjuvant chemotherapy for early-stage breast cancer.
Methods: Seventy-three premenopausal women who underwent adjuvant chemotherapy for early stage (stages I to III)
breast cancer were analyzed. Patient clinical characteristics, treatment regimes, menstrual information, and serum
hormone values were collected retrospectively. Characteristic factors relevant to the onset of CIA and menopause were
also estimated.
Results: Approximately 83.6% of patients developed CIA. Older patients (>40 years old) had higher CIA incidence
compared with younger patients (P <0.0001). The onset of menopause was correlated with age (P <0.0001) and
tamoxifen use (P = 0.0313). On the basis of the Kaplan–Meier analysis, a significant difference was observed in the time
of onset of permanent amenorrhea as determined by menstrual history and hormone levels (P = 0.0028). In women
aged 46 to 49 years, the beginning of permanent amenorrhea was detected earlier via the clinical method than via the
hormonal method (2 months versus 23 months, P <0.0001). In the analysis of patients ≥50 years old, the median time to
detection of permanent amenorrhea was 19 months in the hormonal test and 2 months in the clinical test (P = 0.0112).
Conclusions: Age at diagnosis is a predictor of the onset of amenorrhea and transformation into menopause among
premenopausal breast cancer patients. Adjuvant tamoxifen therapy substantially affects the onset of menopause. A delay
of the onset of serum hormone postmenopausal status was observed compared with clinical symptoms. This interval
was approximately 21 months in patients aged 46 to 49 years and 17 months in patients aged over 50 years. This
interval is significant in the clinical estimate of the menstrual status.
Keywords: Breast cancer, Chemotherapy-induced amenorrhea, Estradiol, Follicle-stimulating hormone* Correspondence: dengyongchuanzju@gmail.com
†Equal contributors
1Department of Surgical Oncology, The Second Affiliated Hospital, College of
Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province
310009, China
Full list of author information is available at the end of the article
© 2013 Meng et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Meng et al. World Journal of Surgical Oncology 2013, 11:101 Page 2 of 7
http://www.wjso.com/content/11/1/101Background
Breast cancer accounts for 28% of newly diagnosed
malignancies among women [1], and almost 25% of those
in Western countries occur in premenopausal females [2].
Conversely, the majority of newly diagnosed breast
cancers in China are premenopausal females (with age
ranging from 40 to 49 years) [3]. As more breast cancer
patients benefit from the widespread use of adjuvant
chemotherapy [4], long-term side effects, particularly
ovarian suppression, become a major concern among
women of reproductive age [5]. Ovarian function assessment
after chemotherapy in premenopausal or perimenopausal
women with hormone-receptor-positive breast cancers
is critical in clinical decision making, particularly in cases
involving primary adjuvant endocrine therapy. More than
one-half (52.2 to 77.7%) of the number of premenopausal
women experience chemotherapy-induced amenorrhea
(CIA) [6,7], which results in infertility, psychological
distress, and prolonged exposure to risks of menopause.
Patient age, intensity of chemotherapy, and tamoxifen
dosage are primary determinants of CIA. Older women
(>40 years) have a higher risk of developing amenorrhea
after adjuvant chemotherapy [8-10]. Previous reports
indicated the relevance between currently used chemo-
therapy regimens (anthracycline-based, taxane-based, and
cyclophosphamide/methotrexate/fluorouracil (CMF) regi-
mens) and the onset of CIA [9,11-14]. The occurrence of
amenorrhea is frequently associated with the cumulative
dosage of chemotherapy [12,14]. The effect of tamoxifen
on menstrual cessation has also been determined in several
multi-central randomized controlled clinical trials [13,15,16].
However, most of the evidence comes from women in
Western countries. Evidence of the occurrence and
characteristic factors of CIA among Asian women remains
insufficient.
In this study, we conducted a retrospective analysis to
assess the onset of CIA and menstruation resumption.
Potential factors relevant to CIA and menstruation
resumption were determined by employing univariate
analysis. Differences in the evaluation efficacy of ovarian
function between two methods (menstrual history and
hormonal levels) were also discussed.
Methods
Patients and treatments
We conducted a retrospective analysis of newly diagnosed
premenopausal breast cancer patients managed at the
Second Affiliated Hospital of Zhejiang University between
1 January 2007 and 1 September 2011. Participants were
eligible for further analysis if they met the following inclu-
sion criteria: (1) newly diagnosed early breast cancer
(stages I to III); (2) premenopausal hormone levels and at
least two menstrual periods in the preceding 6 months;
(3) periodic follow-up (every 3 months) data, includingclinical follow-up of menstrual history and serum hormone
levels. Patients with gonadotropin-releasing hormone
(GnRH) agonist administration or hysterectomy/bilateral
oophorectomy histories were excluded.
All patients received four to six cycles of systemic
chemotherapy (including anthracycline-based or taxane-
based regimens). Patients with hormone-receptor-positive
breast cancers were given tamoxifen as endocrine therapy
after the termination of adjuvant chemotherapy.
Data collection
All patients provided verbal consent for their clinical
information to be reviewed by investigators. Clinical data
(including patient age, tumor stage and size, nodal stage,
estrogen receptor, progesterone receptor and Her-2/neu
status, chemotherapy regimen and dosage, radiation ther-
apy, trastuzumab administration, and endocrine therapy)
was collected from electronic medical records at the
Second Affiliated Hospital of Zhejiang University. Infor-
mation on menstrual history, relapse, or metastasis status
was obtained during each follow-up.
Serum estradiol (E2) and follicle-stimulating hormone
(FSH) were tested by using chemiluminescence immuno-
assay via the ADVIA Centaur System (Siemens Diagnostics,
Tarrytown, NY, USA). According to the protocol of the
chemiluminescence immunoassay kit, postmenopausal
hormone levels are defined as FSH level >21.7 IU/L and
E2 <110 pmol/L. Premenopausal levels are defined as
FSH ≤21.7 IU/L and E2 ≥110 pmol/L. Data on serum E2
and FSH levels was gathered from electronic medical
records. The latest serum E2 and FSH levels were selected
to determine the menstrual status of the patients.
CIA was defined as amenorrhea that occurred within 6
months after the first cycle of chemotherapy. Menstrual
histories provided by participants were used to determine
clinical ovarian function regardless of hormone levels.
Permanent amenorrhea was defined as having no history
of menstrual bleeding after CIA during follow-up. If both
E2 and FSH returned to premenopausal levels after
the occurrence of CIA, the condition was defined as
“harmonic reversible amenorrhea,” regardless of menstrual
bleeding. Similarly, menopause was defined in terms of E2
and FSH levels simultaneously within postmenopausal
hormone levels after the occurrence of permanent
amenorrhea.
Statistical analysis
Fisher’s exact tests and chi-square tests were employed
to evaluate the correlations between amenorrhea and
other variables, including age at diagnosis, surgery
treatment, chemotherapy regimen, radiation therapy,
adjuvant endocrine therapy, and trastuzumab treatment.
The chi-square test was used to assess the difference
between the groups of included and excluded patients.
Figure 1 Age is a critical factor influencing the onset and
persistence of chemotherapy-induced amenorrhea. The rate
of amenorrhea in a single age group at a certain follow-up duration
is determined based on the following formula: rate of amenorrhea =
(number of patients who experienced amenorrhea in a particular
age group)/(total number of patients in that age group with
available follow-up information).
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and 36 months after initial chemotherapy) were calculated
via Fisher’s exact tests.
Among the patients with CIA, the proportions of certain
menstrual patterns (reversible amenorrhea or menopause)
between treatment regimens and age groups were also
assessed via Fisher’s exact tests and chi-square tests. The
Kaplan–Meier method was conducted to compare the
differences of amenorrhea duration between age
groups. The duration between chemotherapy beginning
and menstruation resumption determined by clinical
definition or hormone measurement was examined via the
Kaplan–Meier method. The time of onset of permanent
amenorrhea determined by the aforementioned two
methods was also evaluated via the Kaplan–Meier
method. All statistical tests were two-sided, and P values
<0.05 were considered statistically significant.
Results
Patient characteristics
We reviewed the medical records of 368 premenopausal
breast cancer patients who received radical surgery
(including modified radical mastectomy and breast-
conserving surgical operation) and systemic chemotherapy
at our institution. Among the patients, 295 were excluded
from the study for the following reasons: 275 patients had
insufficient hormone records, 12 patients received GnRH
agonist administration after breast cancer diagnosis, 48
patients received bilateral oophorectomy or hysterectomy,
12 patients lack information on their menstruation status,
and 27 patients failed to follow-up (several patients were
excluded for two or more of the aforementioned reasons).
Consequently, 73 patients were eligible for analysis. The
median follow-up duration was 27 months (ranging from
10 months to 52 months).
The median age of the 73 patients was 44 years (the
age range was 27 to 55 years). The characteristics of
patients are shown in Additional file 1 (Table S1). The
majority (67.1%) of the patients were aged between 40
and 49 years old. Most of the patients (45.2%) received
chemotherapy, including both anthracycline and taxane.
A total of 64 patients (87.7%) received tamoxifen as
adjuvant hormone therapy. The most significant patient
clinical characteristics (for example, age, chemotherapy
regimens and tamoxifen intake) in the included group (73
patients) and in the excluded group (295 patients) were
almost the same, as shown in Additional file 1 (Table S1).
Analysis of change in either menstrual history or serum
hormone levels
A total of 61 women (83.6%) developed CIA after initial
chemotherapy. Among the patients who experienced
amenorrhea, CIA occurred more frequently in those
older than 40 years (P <0.0001). The incidence ofmenstrual cessation is statistically correlated with age at
diagnosis (P <0.0001), whereas the types of chemotherapy
regimen, tamoxifen intake, trastuzumab treatment,
and radiation therapy were not associated with CIA
development (see Additional file 1, Table S2).
Among the women who experienced CIA, 28 experienced
menstruation resumption in the follow-up periods. The
probability of vaginal bleeding was more significant in
the younger group (≤45 years) than in others (>45 years)
(P <0.0001). The median time of menstruation resumption
after amenorrhea was 7 months (the range was 3 months
to 17 months). The percentage of CIA in young patients
(≤45 years) declined after chemotherapy. However, the
trend was not remarkable among old patients (>45 years).
During each succeeding period, patients >45 years old
usually maintain amenorrhea status once CIA occurred
(see Figure 1).
Combined with hormone tests, only 22 patients
(30.1%) reached postmenopausal serum hormone levels
after the occurrence of CIA during the follow-up period.
Patients younger than 45 years at diagnosis were less
likely to develop menopause compared with those older
than 45 years (P <0.0001). Patients on tamoxifen therapy
had higher risk of menopause regardless of age (P = 0.0313)
(see Additional file 1, Table S3).
Nine patients exhibited persisting amenorrhea status
although their hormone values were under premenopausal
levels (see Additional file 1, Table S4). On the basis of the
data presented in Additional file 1 Table S4, age at diagnosis
statistically affects the incidence of CIA, restoration of
menses, and menopause.
Figure 2 Clinical cessation of menstrual bleeding is an event
occurring earlier than attained serum postmenopausal
hormonal levels. Rates of permanent amenorrhea determined by
clinical history and serum hormonal levels in (A) general patients,
(B) patients aged 46 to 49 years, and (C) patients aged ≥50 years old.
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menstrual history and serum hormone levels
Among the patients who experienced CIA, many main-
tained amenorrhea clinically without the simultaneous
biochemical evaluations of ovarian depression. Kaplan–
Meier analysis results showed a significant difference in the
time of onset of permanent amenorrhea, which was deter-
mined by menstrual history and hormone levels (P =
0.0028) (see Figure 2). In women aged 46 to 49 years, the
beginning of permanent amenorrhea was detected earlier
according to the clinical method than according to
the hormonal method (2 months versus 23 months,
P <0.0001) (see Figure 2). In the analysis of patients ≥50
years old, the median time to detection permanent amen-
orrhea was 19 months in the hormonal test, and 2 months
in the clinical test (P = 0.0112) (see Figure 2).
In patients who regained ovarian function, no difference
in ovarian depression duration was detected between
menstrual history and the hormonal method via Kaplan–
Meier analysis (see Figure 3). However, in the group
younger than 45 years old, the median ovarian depression
duration was shorter via the clinical method than that via
the hormonal method (8 months versus 16 months,
respectively, P = 0.0101) (see Figure 4). No difference was
detected between the two methods among the group of
patients older than 45 years.
Discussion
CIA is one of the frequent therapy-related adverse events
observed in patients who undergo chemotherapy. CIA is a
significant drain on the quality of life of cancer patients
because of its associated menopausal symptoms and
potential risk of infertility. In this study, we conducted a
retrospective analysis to assess the onset of CIA and
menstruation transformation among Chinese women
who underwent chemotherapy for breast cancer. A total
of 73 premenopausal breast cancer patients were in-
cluded in this study, whereas 295 patients were
excluded for various reasons. The major clinical charac-
teristics in the included group (73 patients) and in the
excluded group (295 patients) were almost the same. Al-
though only 19.8% of the potential group is included in
our analysis, the potential selection bias is limited.
In this study, the rate of CIA (83.6%) was similar to
the data provided by other trials. In the International
Breast Cancer Study Group trial 13–93 [17], the general
incidence of CIA was 86%, which is approximately equal
to our results. Han and colleagues reported that the rate
of CIA in the Korean population was 89.1% [13]. However,
the incidence of CIA was lower (68%) in the findings of
Lee and colleagues [16]. The differences may have resulted
from the different age compositions among these studies.
The higher component ratio of included patients who
were ≥40 years old (78.1% in our study versus 61% in thestudy of Lee and colleagues) may be attributed to the
higher rate of CIA onset in our study.
Previous evidence indicates the incidence of CIA depends
on the patient age or type and intensity of chemotherapy or
tamoxifen dosage [18]. In this study, we also discussed
these potential factors on the onset of CIA and the trans-
formation to menopause via univariate analysis. Our study
Figure 3 No difference in ovarian depression duration was
detected between menstrual history and hormonal method.
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encing factor on the onset of CIA, which is in accordance
with previous studies [7,17,19-22]. Age at diagnosis was
also a major predictor for both reversible amenorrhea and
menopause, as shown in Additional file 1 Table S4.
Additionally, we found that Chinese women younger than
40 years who experienced CIA had higher incidence of
menstruation resumption. Similar results were reported in
other Asian-based studies [13,16], as well as in Western
studies [6,22]. Patients aged ≤45 years old were less likely
to develop menopause after CIA and more likely to ex-
perience menstruation resumption or maintain amenor-
rhea, as confirmed by both clinical manifestation and
serum hormone status in the study.
Previous evidence indicates that tamoxifen is a potential
influencing factor of CIA onset. In this study, the
relevance between the administration of tamoxifen
and CIA was not significant in the univariate analysis.
However, this relevance was influenced by the age of theFigure 4 Clinical resumption of menstrual bleeding is an event
occurring earlier than attained serum premenopausal
hormonal levels in determining ovarian depression after
chemotherapy-induced amenorrhea in patients aged ≤45 years.patient at diagnosis [20,22]. Given the limited number of
patients in different age-based subgroups, conducting
subgroup analysis, as well as determining the association
between the tamoxifen and patient age, is difficult. Our
data indicated that the addition of tamoxifen substantially
affected the onset of menopause. The possible explana-
tions are the disturbance of negative feedback from the
hypothalamus to the ovary [18] and the depression of pitu-
itary production triggered by tamoxifen [23,24].
Menstrual status determined by the history of menstrual
bleeding is a conventional and convenient method of
assessment in determining ovarian function [9]. However,
menstrual status cannot thoroughly reflect actual ovarian
function [25]. The serial measurement of serum ovarian
biochemical markers is an acceptable method to reflect
ovarian function. Accordingly, in this study, we determined
patient menstrual status by employing both clinical
menstrual history and serum ovarian biochemical
markers. We compared the differences in the median time
to onset of permanent amenorrhea between the aforemen-
tioned two approaches. Our results indicate that the time
of clinical cessation of menses was earlier than the
recorded serum postmenopausal hormonal levels. As
shown in our study, for Asian patients aged between 46
and 49 years, another 21 months were needed for hor-
mone levels to reach the postmenopausal range after the
cessation of menses. For patients older than 50 years, an-
other 17 months were necessary. The World Health
Organization defined 12 months of amenorrhea as an in-
dication of menopause [26]. On the basis of our results,
this criterion is not reasonable for identifying women who
experienced premature amenorrhea after cytotoxic therapy.
Accordingly, the serial measurement of serum FSH and E2
combined with menstrual history are suggested as an as-
sessment for ovarian function [27]. Given the complexity
of ovarian change after chemotherapy, the duration of
hormone measurement after amenorrhea onset for
postmenopausal status confirmation is uncertain. The
guidelines provided by the National Comprehensive
Cancer Network suggest a postmenopausal range of 12
months to meet the criteria for menopause. However,
most studies support the regular monitoring of hormone
status without mentioning the duration [27,28]. We
propose that the clinical history and serum hormone level
follow-up duration should last for at least 21 months for
patients aged 45 years to 49 years and 17 months for
patients aged ≥50 years to determine the exact menstrual
status among Asian women.
Previous studies preferred FSH as a biochemical marker
to predict ovarian reserve [26]. The role of FSH in
accessing ovarian function has been well demonstrated.
Other than FSH, anti-Müllerian hormone (AMH) and in-
hibin B are also shown to improve the predictive capacity
of ovarian function [29,30]. AMH and inhibin B appear to
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administration of tamoxifen [30]. Moreover, AMH and in-
hibin B reflect subtle changes in menstrual transition, which
has been compared with FSH. AMH is also strongly
recommended for its sensitivity in predicting ovarian
function and stable expression over the menstrual cycle
[25]. With regard to biophysical parameters, antral follicle
count (AFC) is also a useful parameter. The function of
AFC in assessing ovarian function among children cancer
survivors has been proven [31]. Reduced AFC was
observed in breast cancer patients after chemotherapy and
appeared to be in accordance with suppressed ovarian
function [25]. Further investigation is necessary to confirm
the function of such biomarkers in clinical application.
Our study had several limitations, such as a short
follow-up period and small sample size. As previously
stated, the large proportion of patients dropping out of
the study was assumed to have resulted from the lack of
periodic hormone values. Approximately 26% hormone
insensitivity and poor adherence would be the possible
reasons for the missing information, which introduced
bias. The small number for certain groups (for example,
patients without amenorrhea) can affect the precision
of CIA rates in perimenopausal breast cancers. As a
retrospective study, the menstrual status might be less
reliable due to a recall bias. Despite these limitations,
our study is an effective exploration of time points and
intervals between them to predict the ovarian function
pattern during follow-up. A more comprehensive study
with a longer follow-up period and written diaries of
patients is planned by our institution in this area. In
addition, other hormone markers, including AMH and
inhibin B, could be assessed serially in determining
post-chemotherapy ovarian reserve, and the related cutoff
point for these biomarkers could be evaluated.
Conclusions
An accurate and probable evaluation of ovarian function
promotes better understanding of the effect of cytotoxic
agents, thereby offering cancer patients useful information
with respect to appropriate endocrine therapy and fertility
preservation.
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Additional file 1: The file name Table-wjso.xls includes the
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paper. All tables are shown in Sheet 1.
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